IL6R and teratocarcinoma: IL-6R was identified as a direct target of miR-let-7a, and the miR-let-7a inhibitor significantly increased the level of IL-6R expression, resulting in increased proliferation, reduced apoptosis, and inhibited inflammatory response in ATDC5 cells, which are derived from mouse teratocarcinoma [132].